Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Keppra XR is a prescription extended-release antiseizure medicine containing levetiracetam. It is indicated for treatment of partial-onset seizures in patients age 12 and older. Current tablets contain 500 mg or 750 mg.
read more about keppra xr ...The exact antiseizure mechanism of levetiracetam is not established. Levetiracetam binds to synaptic vesicle protein SV2A, and this interaction is associated with its antiseizure activity.
Keppra XR is used for partial-onset seizures in patients age 12 and older. The extended-release formulation is taken once daily and has a narrower labeled seizure indication than immediate-release Keppra.
Treatment starts at 1000 mg once daily and can increase by 1000 mg every two weeks to a maximum recommended dose of 3000 mg once daily. Adult kidney impairment requires lower once-daily doses according to creatinine clearance. Extended-release tablets are swallowed whole and are not chewed, broken, or crushed.
Serious concerns include behavioral abnormalities, psychotic symptoms, suicidal thoughts or behavior, somnolence, dizziness, anaphylaxis, angioedema, severe skin reactions, and DRESS. Abrupt withdrawal can increase seizure frequency or trigger status epilepticus, so treatment is withdrawn gradually.
Keppra XR treats partial-onset seizures in patients age 12 and older.
The recommended starting dose is 1000 mg once daily.
The maximum recommended dose is 3000 mg once daily.
No. The extended-release tablets are swallowed whole.
KEPPRA XR (Levetiracetam) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2919e43b-69a8-434c-a2d2-1f3ecd7554c0. Date Accessed October 7, 2026.
Levetiracetam Extended Release as Adjuvant Therapy for the Control of Partial-Onset Seizures. https://pubmed.ncbi.nlm.nih.gov/23861635/. Date Accessed October 7, 2026.
Levetiracetam Extended Release for the Treatment of Patients With Partial-Onset Seizures: A Long-Term, Open-Label Follow-Up Study. https://pubmed.ncbi.nlm.nih.gov/26716580/. Date Accessed October 7, 2026.
Levetiracetam: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a699059.html. Date Accessed October 7, 2026.
Once-Daily Extended-Release Levetiracetam as Adjunctive Treatment of Partial-Onset Seizures in Patients With Epilepsy: A Double-Blind, Randomized, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/19317886/. Date Accessed October 7, 2026.